SCHEMBL20181565

SCHEMBL20181565

CCc1nc2cc(OC)ccn2c1C(=O)c1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 5/20 0.43
ADORA3 P0DMS8 6/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
ALOX15 P16050 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ADORA2A P29274 2/20 0.36
ADORA1 P30542 2/20 0.36
METTL3 Q86U44 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CYP1A2 P05177 1/20 0.35
PGR P06401 1/20 0.35
CYP2D6 P10635 1/20 0.35
HPGD P15428 1/20 0.35
SLC6A2 P23975 1/20 0.35
PDE4A P27815 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP2C19 P33261 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20181564 0.93 LMNA (0.43) ALDH1A1LMNAALOX15NPSR1NPC1
SCHEMBL20181563 0.87 SLC22A12 (0.39) SLC22A12LMNANPC1RAB9AHPGD
SCHEMBL20181566 0.85 SLC22A12 (0.46) SLC22A12ADORA3ALDH1A1LMNAMETTL3
SCHEMBL23092199 0.83 ADORA3 (0.42) ADORA3ADORA1METTL3NPC1RAB9A
SCHEMBL21387381 0.82 SLC22A12 (0.41) SLC22A12ADORA3METTL3NPC1RAB9A
SCHEMBL18629834 0.79 MAPK1 (0.50) ALDH1A1NPSR1NPC1CYP1A2HPGD
SCHEMBL18629838 0.79 SMN1; SMN2 (0.52) ALDH1A1LMNANPSR1NPC1RAB9A
SCHEMBL20181666 0.77 MAPT (0.43) ALDH1A1LMNAALOX15NPSR1RAB9A
SCHEMBL22623399 0.77 DRD2 (0.44) ALDH1A1LMNAALOX15NPSR1NPC1
SCHEMBL20181578 0.77 CYP19A1 (0.46) ALDH1A1LMNAALOX15NPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50083-E1 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2024-08-20 US disclosed
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-08-20 US disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
WO-2018090921-A1 URAT1 INHIBITOR AND USE THEREOF 江苏新元素医药科技有限公司 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 SLC22A12 35/4885ADORA3 1214/4885ALDH1A1 326/4885
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF SLC14A1, SLC10A6, SLC10A1 SLC22A12 39/4885ADORA3 2415/4885ALDH1A1 356/4885
US-10875865-B2 URAT1 inhibitor and use thereof SLC14A1, SLC10A6, SLC10A1 SLC22A12 39/4885ADORA3 2415/4885ALDH1A1 356/4885
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION SLC10A6, SLC10A1, SLC28A1 SLC22A12 35/4885ADORA3 1214/4885ALDH1A1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.